Differential effects of strength training and testosterone treatment on soluble CD36 in aging men: Possible relation to changes in body composition

Purpose. We measured soluble CD36 (sCD36) and body composition to determine the effects of testosterone treatment (TT) and/or strength training (ST) on cardiovascular risk in men with low normal testosterone levels. Methods. Double-blinded, placebo-controlled study in 54 men aged 60–78 years with bioavailable testosterone < 7.3 nmol/L and waist > 94 cm randomized to TT (gel, 50–100 mg/day, n = 20), placebo (n = 18) or ST (n = 16) for 6 months. Moreover, the ST group was randomized to TT (ST + TT, n = 7) or placebo (ST + placebo, n = 9) after 3 months. Outcomes. sCD36, total and regional fat mass were established by Dual X-ray absorptiometry and magnetic resonance imaging. Data are presented as median (quartiles). Kruskal-Wallis and Mann-Whitney tests were performed on delta values at 0, 3 and 6 months. Results. ST + placebo decreased sCD36 levels by 21% [from 0.80 (0.68–1.22) to 0.63 (0.51–0.73) rel. units] vs. TT and vs. placebo (p < 0.05). ST + placebo did not change bioavailable testosterone and lean body mass. Fat mass measures significantly improved during ST + placebo, ST + TT, and TT vs. placebo. During ST + placebo, delta sCD36 was associated with delta total fat mass (r = 0.81) and delta central fat mass (r = 0.84). Conclusions. Compared to testosterone treatment, six months of strength training reduced sCD36 levels suggesting decreased cardiovascular risk, possibly due to a reduction in central fat mass.

[1]  H. Vestergaard,et al.  Circulating sCD36 is associated with unhealthy fat distribution and elevated circulating triglycerides in morbidly obese individuals , 2014, Nutrition & Diabetes.

[2]  S. Greenland,et al.  Increased Risk of Non-Fatal Myocardial Infarction Following Testosterone Therapy Prescription in Men , 2014, PloS one.

[3]  K. Madsen,et al.  Mechanical Muscle Function and Lean Body Mass During Supervised Strength Training and Testosterone Therapy in Aging Men with Low‐Normal Testosterone Levels , 2013, Journal of the American Geriatrics Society.

[4]  B. Cowling,et al.  Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials , 2013, BMC Medicine.

[5]  D. Hougaard,et al.  Strength Training and Testosterone Treatment Have Opposing Effects on Migration Inhibitor Factor Levels in Ageing Men , 2013, Mediators of inflammation.

[6]  K. Højlund,et al.  Osteoprotegerin Levels Decrease During Testosterone Therapy in Aging Men and are Associated with Changed Distribution of Regional Fat , 2012, Hormone and Metabolic Research.

[7]  A. Greenberg,et al.  Sex differences in human adipose tissues – the biology of pear shape , 2012, Biology of Sex Differences.

[8]  John R. Petrie,et al.  Plasma sCD36 is associated with markers of atherosclerosis, insulin resistance and fatty liver in a nondiabetic healthy population , 2012, Journal of internal medicine.

[9]  D. Hougaard,et al.  Testosterone therapy decreases subcutaneous fat and adiponectin in aging men. , 2012, European journal of endocrinology.

[10]  C. Cooper,et al.  Frailty and sarcopenia: definitions and outcome parameters , 2012, Osteoporosis International.

[11]  L. Monti,et al.  Aerobic and resistance training effects compared to aerobic training alone in obese type 2 diabetic patients on diet treatment. , 2011, Diabetes research and clinical practice.

[12]  P. Dandona,et al.  Update: Hypogonadotropic hypogonadism in type 2 diabetes and obesity. , 2011, The Journal of clinical endocrinology and metabolism.

[13]  Rasmus Larsen,et al.  Automatic Segmentation of Abdominal Adipose Tissue in MRI , 2011, SCIA.

[14]  D. Hougaard,et al.  Testosterone therapy increased muscle mass and lipid oxidation in aging men , 2011, AGE.

[15]  A. Handberg,et al.  Soluble CD36− a marker of the (pathophysiological) role of CD36 in the metabolic syndrome? , 2011, Archives of physiology and biochemistry.

[16]  E. Mannucci,et al.  Testosterone, cardiovascular disease and the metabolic syndrome. , 2011, Best practice & research. Clinical endocrinology & metabolism.

[17]  A. Jette,et al.  Adverse events associated with testosterone administration. , 2010, The New England journal of medicine.

[18]  S. Bhasin,et al.  Clinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. , 2010, The Journal of clinical endocrinology and metabolism.

[19]  C. Hagen,et al.  The impact of the CAG repeat polymorphism of the androgen receptor gene on muscle and adipose tissues in 20-29-year-old Danish men: Odense Androgen Study. , 2010, European journal of endocrinology.

[20]  A. Handberg,et al.  Soluble CD36 (sCD36) clusters with markers of insulin resistance, and high sCD36 is associated with increased type 2 diabetes risk. , 2010, The Journal of clinical endocrinology and metabolism.

[21]  J. Frystyk,et al.  Subcutaneous rather than visceral adipose tissue is associated with adiponectin levels and insulin resistance in young men. , 2009, The Journal of clinical endocrinology and metabolism.

[22]  M. Schulze,et al.  General and abdominal adiposity and risk of death in Europe. , 2008, The New England journal of medicine.

[23]  P. H. Petersen,et al.  Visceral and subcutaneous adipose tissue assessed by magnetic resonance imaging in relation to circulating androgens, sex hormone-binding globulin, and luteinizing hormone in young men. , 2007, The Journal of clinical endocrinology and metabolism.

[24]  K. Højlund,et al.  Identification of the Oxidized Low-Density Lipoprotein Scavenger Receptor CD36 in Plasma: A Novel Marker of Insulin Resistance , 2006, Circulation.

[25]  J. Helge,et al.  Diet and exercise reduce low-grade inflammation and macrophage infiltration in adipose tissue but not in skeletal muscle in severely obese subjects. , 2006, American journal of physiology. Endocrinology and metabolism.

[26]  A. Lenzi,et al.  Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle‐aged men: a meta‐analysis , 2005, Clinical endocrinology.

[27]  D. Accili,et al.  Increased CD36 protein as a response to defective insulin signaling in macrophages. , 2004, The Journal of clinical investigation.

[28]  M. Desai,et al.  Obesity is associated with macrophage accumulation in adipose tissue. , 2003, The Journal of clinical investigation.

[29]  M. Sampson,et al.  Increased expression of a scavenger receptor (CD36) in monocytes from subjects with Type 2 diabetes. , 2003, Atherosclerosis.

[30]  R. Silverstein,et al.  CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. , 2001, The Journal of clinical investigation.

[31]  S. Hazen,et al.  Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. , 2000, The Journal of clinical investigation.

[32]  A. Vermeulen,et al.  A critical evaluation of simple methods for the estimation of free testosterone in serum. , 1999, The Journal of clinical endocrinology and metabolism.

[33]  D. Schoenfeld,et al.  Using quantitative CT to assess adipose distribution in adult men with acquired hypogonadism. , 1998, AJR. American journal of roentgenology.

[34]  V. Montori,et al.  Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. , 2007, Mayo Clinic proceedings.

[35]  S. Grundy.  Metabolic syndrome. , 2006, Nature medicine.